AlphaTON Capital Corp. (Nasdaq: ATON) (“AlphaTON” or the “Company”), the world’s leading public technology company developing the Telegram super-app with an addressable market of one billion monthly active users, today announced a market update on its outstanding shares, warrants, options and RSUs. As of February 19, 2026, the Company has in circulation:
-
23,434,588 ordinary shares
-
1,373,686 shares of common stock issuable upon exercise of outstanding warrants, with a weighted average exercise price of $11.62 per share;
-
1,283,931 shares of common stock issuable upon exercise of outstanding pre-funded warrants from the PIPE investment in 2025;
-
316,111 shares of common stock issuable upon the exercise of outstanding stock options under our 2021 Stock Incentive Plan, with a weighted average exercise price of $40.65 per share; And
-
5,410 shares of common stock issuable upon vesting of outstanding restricted stock units under our 2021 Equity Incentive Plan.
About AlphaTON Capital Corp.
AlphaTON Capital Corp (NASDAQ: ATON) is the world’s first public technology company developing the Telegram super-app, with an addressable market of 1 billion monthly active users. The company offers a comprehensive hyperscaler strategy across the Telegram ecosystem through a combination of software products, data middleware and AI training assets, as well as AI infrastructure hardware clusters deploying confidential AI for the Telegram ecosystem.
Through its operations, AlphaTON Capital provides public market investors with institutional-grade exposure to the Telegram ecosystem and its billion-user platform while maintaining the governance standards and reporting transparency of a Nasdaq-listed company. The Company’s activities cover AI Confidential Compute, network validation and staking operations, Telegram-based application development, including strategic investments and acquisitions of decentralized financial platforms, gaming and marketplaces, as well as commercial applications.
AlphaTON Capital Corp is incorporated in the British Virgin Islands and is listed on Nasdaq under the symbol “ATON”. AlphaTON Capital, through its legacy businesses, is also advancing first-in-class therapies targeting known checkpoint resistance pathways to achieve durable therapeutic responses and improve patient quality of life. AlphaTON Capital actively engages in the drug development process and provides strategic advice to guide the development of new immunotherapy assets and combinations of assets.
Website: https://alphatoncapital.com
Telegram: https://t.me/alphatoncapital_official
X: https://x.com/AlphaTONCapital
LinkedIn:
Forward-looking statements
All statements contained in this press release, other than statements of historical fact, including, without limitation, statements regarding the Company’s business strategy, management’s plans and objectives for future operations and statements preceded, followed by or otherwise including the words “believe”, “expects”, “anticipates”, “intends”, “estimates”, “will”, “may”, “plans”, “potential”, “continue”, or similar expressions or variations of these expressions are forward-looking statements. Accordingly, forward-looking statements are subject to certain risks and uncertainties, including, but not limited to: the risk that the Company may not be able to obtain additional financing or TON, the uncertainty of the Company’s investment in TON, the uncertainty around the Company’s historical business, the Company’s operational strategy, the Company’s management team, risks related to the Telegram platform and ecosystem, the potential impact of markets and other general economic conditions, and other factors set forth in “Item 3 – Key Information – Risk Factors” in the Company’s Annual Report on Form 20-F for the fiscal year ended March 31, 2025 and included in the Company’s Form 6-K filed with the Securities and Exchange Commission on September 3, 2025 and January 13, 2026. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, they should not place undue reliance on them as actual results may differ materially from these forward-looking statements. The forward-looking statements contained in this press release are made as of the date hereof and the Company undertakes no obligation to publicly update or revise any forward-looking statements or information, except as required by law.
Investor relations:
John Ragozzino, CFA
(email protected)
(203) 682-8200
Media inquiries:
Richard Laermer
RP RLM
(email protected)
(212) 741-5106 ext. 216
